Close

Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.48/Shre

May 10, 2017 8:47 AM EDT
Get Alerts PLX Hot Sheet
Price: $1.26 +0.80%

Financial Fact:
OPERATING LOSS: -6.65M

Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE

Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.48), versus ($0.09) reported last year. Revenue for the quarter came in at $2.9 million versus the consensus estimate of $679 thousand.

  • Positive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development
  • First Ever Once Monthly Dosing Trial in Fabry Patients to Commence Next Quarter
  • Continued Progress in the Commercialization of alfataliglicerase in Brazil

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings